Phentermine costs $10 per month and produces 5 to 10% body weight loss over 12 weeks. Semaglutide (Ozempic/Wegovy) costs $200 to $500 per month and produces about 15% loss over 68 weeks. Tirzepatide (Mounjaro/Zepbound) costs $300 to $1,000 per month and produces about 22% loss over 72 weeks. Those three numbers explain most of the decision.
Phentermine is a 65-year-old stimulant that works by flooding your brain with norepinephrine. GLP-1 drugs are a new class that mimic gut hormones. They work through completely different mechanisms, have different risk profiles, and are prescribed for different durations. Phentermine is a sprint. GLP-1 is a marathon.
| Feature | Phentermine | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) |
|---|---|---|---|
| Weight loss | 5-10% | ~15% | ~22% |
| Duration | 12 weeks max | Long-term | Long-term |
| Cost/month | $8-50 | $199-499 | $299-1,086 |
| Mechanism | Stimulant (norepinephrine) | GLP-1 receptor agonist | GLP-1 + GIP dual agonist |
| DEA schedule | Schedule IV | Not controlled | Not controlled |
| Administration | Oral tablet, daily | Weekly injection | Weekly injection |
| CV safety data | No long-term data | 20% CV risk reduction (SELECT) | Pending |
| Side effects | Stimulant (insomnia, jitters) | GI (nausea, diarrhea) | GI (nausea, diarrhea) |
| FDA approved | 1959 | 2021 | 2022 |
This article compares mechanism, efficacy, cost, safety, side effects, and practical considerations for choosing between phentermine and GLP-1 medications.
This is educational content. Consult a healthcare provider before starting any medication.
Get your custom peptide protocol:
- Tailored to your body and goals
- Precise dosing and cycle length
- Safe stacking combinations
- Backed by peer-reviewed studies
- Ready in under 2 minutes
How They Work
Phentermine and GLP-1 drugs suppress appetite through completely different biological pathways.
Phentermine: The Stimulant Approach
Phentermine is a sympathomimetic amine, essentially a mild amphetamine. It activates the TAAR1 receptor in the brain and stimulates the release of norepinephrine and epinephrine (adrenaline). This triggers a "fight or flight" response that suppresses appetite, increases energy, and elevates heart rate.
The drug was FDA-approved in 1959 and has been the most prescribed weight loss medication in America for decades. It is available as 15 mg or 37.5 mg tablets taken once daily in the morning (to avoid insomnia). It is classified as a DEA Schedule IV controlled substance due to its structural similarity to amphetamines.
Phentermine's appetite suppression tends to diminish over 8 to 12 weeks as the body develops tolerance. This is why prescriptions are typically limited to 12 weeks. Some practitioners prescribe it in intermittent cycles (month on, month off), though this is off-label.
GLP-1 Drugs: The Hormone Approach
Semaglutide and tirzepatide mimic natural gut hormones that your body releases after eating. Semaglutide activates GLP-1 receptors, which slow gastric emptying, suppress appetite through brainstem signaling, and reduce "food noise" (the constant mental preoccupation with food). Tirzepatide adds GIP receptor activation, which improves metabolic signaling and amplifies weight loss.
Unlike phentermine, GLP-1 drugs do not develop tolerance. They maintain appetite suppression indefinitely as long as the patient continues treatment. This is why they are prescribed for long-term use, and why stopping leads to weight regain (see our tirzepatide before and after guide for discontinuation data).
GLP-1 drugs are not stimulants. They do not increase heart rate or cause jitteriness. They are not DEA-controlled substances.
Weight Loss Comparison
| Drug | Weight Loss | Timeframe | % Who Lose 10%+ | Source |
|---|---|---|---|---|
| Phentermine 37.5 mg | 5-10% | 12 weeks | ~50% | Multiple studies |
| Semaglutide 2.4 mg | 14.9% | 68 weeks | 69% | STEP 1 |
| Tirzepatide 15 mg | 22.5% | 72 weeks | 90% | SURMOUNT-1 |
Phentermine produces faster initial results. Most patients lose 3 to 5% of body weight in the first month, compared to 1 to 3% on GLP-1 drugs. The difference: phentermine's effect plateaus by month 3, while GLP-1 drugs continue producing weight loss for 12 to 18 months.
A systematic review published in JAMA Network Open ranked obesity medications by efficacy: tirzepatide > semaglutide > phentermine-topiramate (Qsymia) > phentermine alone > orlistat. Semaglutide was specifically noted to have "superior efficacy" with "additional cardiometabolic benefits" compared to phentermine.
For detailed week-by-week timelines, see our tirzepatide before and after results and our semaglutide before and after guide.
Cost Comparison
The cost difference is the primary reason phentermine still has a market despite lower efficacy.
| Drug | Monthly Cost (Cash) | Monthly Cost (Insurance) | Annual Cost (Cash) |
|---|---|---|---|
| Phentermine (generic) | $8-50 | $5-15 copay | $96-600 |
| Semaglutide (Wegovy) | $199-499 (self-pay) | $0-50 copay | $2,388-5,988 |
| Tirzepatide (Zepbound) | $299-499 (LillyDirect) | $25 w/ savings card | $3,588-5,988 |
| Semaglutide (compounded) | $150-299 | Not covered | $1,800-3,588 |
| Tirzepatide (compounded) | $200-399 | Not covered | $2,400-4,788 |
Phentermine is 10x to 50x cheaper than GLP-1 drugs on a monthly basis. A full 12-week course of phentermine costs less than a single month of brand-name Wegovy.
This cost gap explains why phentermine remains the most prescribed weight loss drug in America despite producing less weight loss. For patients without insurance coverage for GLP-1 drugs, phentermine may be the only affordable pharmaceutical option.
For GLP-1 pricing details, see our tirzepatide cost with insurance guide. For compounded options, see our compound semaglutide with B12 guide.
Side Effects Comparison
The side effect profiles are entirely different because the mechanisms are different.
| Side Effect | Phentermine | Semaglutide | Tirzepatide |
|---|---|---|---|
| Nausea | Uncommon | 44% | 31% |
| Diarrhea | Uncommon | 30% | 23% |
| Constipation | 10-15% | 24% | 12% |
| Insomnia | 20-30% | Uncommon | Uncommon |
| Dry mouth | 20-30% | Uncommon | Uncommon |
| Jitteriness/anxiety | 15-20% | Uncommon | Uncommon |
| Heart rate increase | Significant | Mild (1-3 bpm) | Mild (1-3 bpm) |
| Headache | 10-15% | 14% | 10% |
| Hair loss | Uncommon | Reported | Reported |
Phentermine's side effects are stimulant-related: insomnia, dry mouth, jitteriness, elevated heart rate. GLP-1 side effects are GI-related: nausea, diarrhea, constipation.
The practical difference: phentermine side effects are constant for the duration of treatment. GLP-1 side effects are worst during dose escalation (first 4 to 16 weeks) and improve significantly once you reach a stable dose.
For managing GLP-1 side effects, see our guides on semaglutide nausea, semaglutide fatigue, and tirzepatide hair loss.
Cardiovascular Safety
This is where GLP-1 drugs have the most significant advantage over phentermine.
The SELECT trial (NEJM 2023) demonstrated that semaglutide reduced major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% compared to placebo in patients with obesity and established cardiovascular disease. This is the first obesity drug to show cardiovascular benefit.
Phentermine has no long-term cardiovascular safety data. It increases heart rate and blood pressure, which are risk factors for cardiovascular events. The 12-week prescribing limit exists partly because of these cardiovascular concerns. Phentermine is contraindicated in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, and history of drug abuse.
Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT) is ongoing, with results expected in 2027.
For patients with cardiovascular risk factors, GLP-1 drugs are clearly preferred over phentermine from a safety standpoint.
When Phentermine Makes Sense
Despite lower efficacy, phentermine is the right choice in specific situations.
Cost is the primary barrier. If you cannot afford $200+ per month for GLP-1 drugs and do not have insurance coverage, phentermine at $10 to $50 per month is the only affordable pharmaceutical option. A 12-week course is better than no treatment.
You need a short-term boost. Phentermine can provide rapid initial weight loss (3 to 5% in the first month) to build momentum for lifestyle changes. Some practitioners use it as a bridge while waiting for GLP-1 insurance approval.
GLP-1 GI side effects are intolerable. If nausea, diarrhea, or vomiting from GLP-1 drugs is severe enough to cause discontinuation, phentermine offers appetite suppression through a different pathway without GI side effects.
After GLP-1 discontinuation. A Healio study explored using phentermine as a bridge medication after stopping GLP-1 drugs to slow weight regain. This approach is experimental but reflects clinical interest in phentermine's utility within a broader treatment strategy.
You only need modest weight loss. If your goal is 10 to 15 pounds rather than 50+, phentermine may achieve it in 12 weeks without the commitment and cost of long-term GLP-1 therapy.
When GLP-1 Is the Better Choice
GLP-1 drugs are preferred in most clinical scenarios.
You need more than 10% body weight loss. Phentermine rarely produces more than 10% loss. GLP-1 drugs routinely produce 15 to 22%.
You have cardiovascular disease or risk factors. Semaglutide has proven cardiovascular benefit (20% risk reduction). Phentermine may increase cardiovascular risk.
You need long-term treatment. Obesity is a chronic condition. Phentermine is limited to 12 weeks. GLP-1 drugs are designed for indefinite use.
You have type 2 diabetes. GLP-1 drugs improve blood sugar control alongside weight loss. Semaglutide (Ozempic) and tirzepatide (Mounjaro) have FDA approval specifically for T2D. Phentermine does not affect blood sugar.
You want sustained appetite suppression. Phentermine develops tolerance by 8 to 12 weeks. GLP-1 drugs maintain effectiveness indefinitely.
Insurance covers GLP-1. If your insurance covers Wegovy, Zepbound, or Mounjaro, the cost differential disappears. Many plans now cover GLP-1 drugs for obesity.
For more on GLP-1 mechanisms and dosing, see our semaglutide dosage chart and tirzepatide dosage chart.
Frequently Asked Questions
Is Ozempic better than phentermine for weight loss?
Yes, in terms of total weight loss. Semaglutide (Ozempic/Wegovy) produces about 15% weight loss versus 5-10% for phentermine. Semaglutide also has proven cardiovascular benefits and can be used long-term. Phentermine is limited to 12 weeks. The main advantage of phentermine is cost: $10-50/month versus $199-499/month for semaglutide.
Can you take phentermine and Ozempic together?
Some physicians prescribe phentermine alongside GLP-1 drugs off-label, particularly during the early titration phase or when weight loss plateaus. This combination is not FDA-approved and should only be done under direct medical supervision due to the different side effect profiles and cardiovascular considerations.
Why is phentermine still prescribed if GLP-1 is better?
Cost. Phentermine costs $10-50/month versus $200-500/month for GLP-1 drugs. Many patients cannot afford GLP-1 medications, and insurance coverage is inconsistent. Phentermine is the most affordable prescription weight loss option available. It also works through a different mechanism, making it an option for patients who cannot tolerate GLP-1 GI side effects.
How much weight can you lose on phentermine in 3 months?
Average weight loss on phentermine is 5-10% of body weight over 12 weeks. For a 250-pound person, that is roughly 12-25 pounds. About 80% of patients lose at least 5%, and about 50% lose 10% or more. Results depend on diet, exercise, and starting weight.
Is phentermine a controlled substance?
Yes. Phentermine is classified as a DEA Schedule IV controlled substance due to its structural similarity to amphetamines. It has mild stimulant properties and a low but real potential for abuse and dependence. This is why prescriptions are typically limited to 12 weeks.
Does phentermine have cardiovascular risks?
Phentermine increases heart rate and blood pressure. It is contraindicated in patients with cardiovascular disease, uncontrolled hypertension, and hyperthyroidism. No long-term cardiovascular safety data exists. In contrast, semaglutide showed a 20% reduction in cardiovascular events in the SELECT trial.
The Bottom Line
The phentermine-versus-GLP-1 decision comes down to three factors: how much weight you need to lose, how long you need treatment, and what you can afford.
Phentermine wins on cost ($10 to $50/month versus $200 to $500+/month) and produces faster initial results. GLP-1 drugs win on total weight loss (15 to 22% versus 5 to 10%), duration (long-term versus 12 weeks max), and cardiovascular safety (proven benefit versus potential risk).
For most patients, GLP-1 drugs are the better clinical choice. For patients who cannot afford GLP-1 therapy and lack insurance coverage, phentermine remains a reasonable option for short-term weight loss.
Use our semaglutide dosage calculator or tirzepatide dosage calculator to understand GLP-1 dosing, and see our peptide cost calculator for treatment cost planning.
This is educational content. Consult a healthcare provider before starting any weight loss medication.
Not Sure Which Peptide Protocol Is Right for You?
Take our 2-minute quiz for a personalized recommendation based on your goals and health profile.
Start the Quiz →